TFG Asset Management GP Ltd Buys Shares of 41,250 Axsome Therapeutics, Inc. (NASDAQ:AXSM)

TFG Asset Management GP Ltd acquired a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 41,250 shares of the company's stock, valued at approximately $3,490,000. Axsome Therapeutics comprises approximately 0.9% of TFG Asset Management GP Ltd's investment portfolio, making the stock its 17th largest position. TFG Asset Management GP Ltd owned about 0.09% of Axsome Therapeutics at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Boxer Capital Management LLC purchased a new stake in Axsome Therapeutics during the 4th quarter worth about $39,767,000. Lazard Asset Management LLC raised its position in shares of Axsome Therapeutics by 525.7% during the 4th quarter. Lazard Asset Management LLC now owns 537,669 shares of the company's stock worth $45,492,000 after acquiring an additional 451,737 shares in the last quarter. Norges Bank purchased a new stake in Axsome Therapeutics during the fourth quarter worth approximately $34,100,000. BVF Inc. IL boosted its holdings in Axsome Therapeutics by 32.7% in the fourth quarter. BVF Inc. IL now owns 1,388,064 shares of the company's stock valued at $117,444,000 after purchasing an additional 342,064 shares in the last quarter. Finally, Principal Financial Group Inc. increased its stake in Axsome Therapeutics by 6,002.7% in the fourth quarter. Principal Financial Group Inc. now owns 207,065 shares of the company's stock valued at $17,520,000 after purchasing an additional 203,672 shares during the last quarter. Institutional investors and hedge funds own 81.49% of the company's stock.

Axsome Therapeutics Price Performance

NASDAQ:AXSM traded down $1.41 during trading hours on Thursday, hitting $104.35. The company's stock had a trading volume of 416,024 shares, compared to its average volume of 687,842. Axsome Therapeutics, Inc. has a 52-week low of $64.11 and a 52-week high of $139.13. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11. The company has a market capitalization of $5.14 billion, a PE ratio of -17.42 and a beta of 0.46. The business's 50-day moving average is $109.68 and its two-hundred day moving average is $105.46.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, beating the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The firm had revenue of $118.77 million during the quarter, compared to the consensus estimate of $117.83 million. As a group, research analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. Bank of America increased their target price on shares of Axsome Therapeutics from $143.00 to $167.00 and gave the company a "buy" rating in a research report on Tuesday, February 11th. Mizuho boosted their price objective on Axsome Therapeutics from $212.00 to $216.00 and gave the company an "outperform" rating in a research note on Thursday, March 27th. Needham & Company LLC restated a "buy" rating and set a $153.00 target price on shares of Axsome Therapeutics in a research report on Tuesday, April 1st. Jefferies Financial Group started coverage on shares of Axsome Therapeutics in a research report on Monday, April 7th. They issued a "buy" rating and a $200.00 price target for the company. Finally, William Blair reiterated an "outperform" rating on shares of Axsome Therapeutics in a research note on Tuesday, February 18th. One investment analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Axsome Therapeutics presently has an average rating of "Buy" and a consensus target price of $172.14.

Insider Buying and Selling at Axsome Therapeutics

In related news, Director Mark Coleman sold 3,000 shares of Axsome Therapeutics stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $107.49, for a total transaction of $322,470.00. Following the completion of the transaction, the director now directly owns 54,137 shares in the company, valued at $5,819,186.13. The trade was a 5.25% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 22.30% of the company's stock.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.